Eflapegrastim

Eflapegrastim (HM-10460A) is a long acting G-CSF analog developed by Hanmi Pharmaceutical and licensed to Spectrum Pharmaceuticals. It was developed for the treatment of chemotherapy-induced neutropenia.[1]

Eflapegrastim
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG

It is in phase III clinical trials comparing the efficacy to that of pegfilgrastim in patients with breast cancer.[2]

References
  1. pharmaceutical, hanmi. "Pipeline - R&D". www.hanmipharm.com.
  2. "RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide - Full Text View - ClinicalTrials.gov".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.